An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Oestrogen Receptor Positive Advanced Breast Cancer
Interventions: DRUG: RAD001|DRUG: Exemestane
Sponsor: Novartis Pharmaceuticals